Cardiometabolic Disorders News

Substantial weight loss after bariatric surgery was associated with improved COVID-19 outcomes compared with nonsurgical controls, including a 49% lower risk for hospitalization and a 60% lower risk for developing severe disease, data show.

Epicardial adipose tissue volume is associated with elevated risk for all-cause death and HF hospitalization in patients with HF with midrange and preserved ejection fraction, according to data published in Circulation: Heart Failure.

Nearly 80% of U.S. adults with obesity and diabetes have hepatic steatosis and an increased risk for advanced fibrosis, according to study findings published in Obesity.

The Healio and Endocrine Today editors have compiled the top meeting news from 2021.

The Healio and Endocrine Today Editors have compiled the top endocrinology news of 2021.

Endocrine Today editors have compiled the top cover stories published in 2021.

Novartis announced the FDA approved inclisiran, its small-interfering RNA therapy for LDL lowering.

Diabetic kidney disease is the leading cause of end-stage renal disease in the U.S., and 50% of adults initiating renal replacement therapy have diabetes, according to the CDC.

One of the first studies I was involved with when I started in diabetes and kidney disease was looking at the predictors of a good outcome when you start therapy. What we use as endpoints in trials is stopping of creatinine decline and end-stage kidney disease. It takes a while to reach these endpoints. It would be ideal, before a patient is at that late stage of disease, to have an indication of whether you are on the right track.

Adults with heart failure with reduced ejection fraction derived similar benefits with empagliflozin regardless of other disease-modifying heart failure therapies prescribed at baseline, post hoc analysis of the EMPEROR-Reduced trial show.